Israel Chemicals Ltd (NYSE:ICL) has earned a consensus rating of “Hold” from the six analysts that are presently covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokers that have covered the stock in the last year is $5.91.

ICL has been the topic of a number of research analyst reports. ValuEngine raised Israel Chemicals from a “hold” rating to a “buy” rating in a report on Friday, August 24th. Zacks Investment Research raised Israel Chemicals from a “sell” rating to a “hold” rating in a report on Wednesday, September 19th. BMO Capital Markets reissued a “hold” rating and set a $5.25 price objective on shares of Israel Chemicals in a report on Wednesday, September 19th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $6.57 price objective on shares of Israel Chemicals in a report on Sunday, October 21st.

Several large investors have recently made changes to their positions in ICL. Lourd Capital LLC acquired a new stake in shares of Israel Chemicals during the 3rd quarter worth approximately $167,000. Citadel Advisors LLC acquired a new stake in shares of Israel Chemicals during the 3rd quarter worth approximately $174,000. AXA acquired a new stake in shares of Israel Chemicals during the 3rd quarter worth approximately $181,000. Janus Henderson Group PLC acquired a new stake in shares of Israel Chemicals during the 3rd quarter worth approximately $201,000. Finally, Eqis Capital Management Inc. acquired a new stake in shares of Israel Chemicals during the 2nd quarter worth approximately $245,000. 9.16% of the stock is currently owned by institutional investors.

ICL traded down $0.18 during midday trading on Thursday, reaching $5.93. The company’s stock had a trading volume of 16,291 shares, compared to its average volume of 212,386. The firm has a market capitalization of $8.21 billion, a P/E ratio of 19.71, a price-to-earnings-growth ratio of 1.79 and a beta of 1.07. The company has a quick ratio of 0.73, a current ratio of 1.34 and a debt-to-equity ratio of 0.44. Israel Chemicals has a twelve month low of $3.85 and a twelve month high of $6.90.

Israel Chemicals (NYSE:ICL) last released its earnings results on Thursday, November 1st. The basic materials company reported $0.10 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.09 by $0.01. The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.38 billion. Israel Chemicals had a return on equity of 13.67% and a net margin of 23.84%. The company’s revenue was down 4.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.09 EPS. As a group, analysts anticipate that Israel Chemicals will post 0.37 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 19th. Stockholders of record on Tuesday, December 4th will be issued a dividend of $0.051 per share. This represents a $0.20 annualized dividend and a dividend yield of 3.44%. The ex-dividend date is Monday, December 3rd. This is a positive change from Israel Chemicals’s previous quarterly dividend of $0.04. Israel Chemicals’s dividend payout ratio (DPR) is presently 32.26%.

About Israel Chemicals

Israel Chemicals Ltd. operates as a specialty minerals company worldwide. The company operates through two segments, Essential Minerals and Specialty Solutions. The company extracts potash from the Dead Sea; mines and produces potash, salt, and Polysulphate; and produces, markets, and sells pure magnesium and magnesium alloys, as well as produces dry carnallite and related by-products, including chlorine and sylvinite.

Featured Story: How Do You Calculate Return on Equity (ROE)?

Receive News & Ratings for Israel Chemicals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Israel Chemicals and related companies with MarketBeat.com's FREE daily email newsletter.